Executive Management

With approximately 28 years of pharmaceutical industry experience, Tim is a founding officer and the current President of RMC Pharmaceutical Solutions Incorporated (RMC). This experience extends across several pharma organizations ranging from large global operations (American Home Products/Wyeth-Ayerst) and mid-size development programs (Amylin Pharmaceuticals), to early-stage/startup companies (FeRx Incorporated and RMC). This uniquely diverse background, includes direct experience spanning the entire GxP (i.e. GLP, GMP and GCP) spectrum of activities that support the pre-clinical/clinical research, CMC/product development and commercialization of regulated drug and device products. This background is not only an asset in the executive team's management of RMC's corporate development and sustained growth, but it has also been vital in allowing Tim to serve RMC clients as a Principal Consultant.

In the role of Principal Consultant, Tim assists clients with creating, developing, and/or executing and achieving their own measured solutions to both the individual and interrelated compliance, quality and development responsibilities of product development and commercialization programs. Additionally, with contemporary hands-on experience evaluating and monitoring GxP quality systems in Asia , North America and Europe, Tim possesses a current global perspective of precisely what is taking place to balance and achieve the varied compliance, quality and overall drug development objectives of numerous organizations throughout these key regions.

Scott is a founding member of RMC Pharmaceutical Solutions, and currently serves as its technical leader. Scott brings 14 years experience in the pharmaceutical industry, and an additional seven years of academic and government sponsored research and development in bioprocessing, to the RMC Pharmaceutical Solutions team. Since joining RMC Pharmaceutical Solutions in May 2004, Scott has been involved in a wide variety of projects for small and large biotech/pharmaceutical companies. He has overseen and/or performed assay, equipment, sterilization, cleaning and process validation, formulation development, due diligence for a multimillion dollar investment, construction of a new GMP facility for tissue processing, and tech transfer for a major late stage biotechnology product. Scott received his PhD in chemical engineering from Purdue University in 1989. In his last position, Scott served as the Vice President of Operations at FeRx Incorporated, overseeing manufacturing, process and product development, analytical development, formulation, facility design, construction and operation, and intellectual property. He is an adjunct professor of chemical engineering at the University of Colorado, a guest researcher at the National Institute of Standards and Technology, and co-author of a leading text book on bioseparations. Scott has also worked at Amylin Pharmaceuticals Incorporated, Synergen Incorporated, and the National Institute of Standards and Technology.